Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. (NASDAQ: VERU) is a late clinical stage biopharmaceutical company whose news flow is closely tied to the development of its two lead small molecule drug candidates, enobosarm and sabizabulin. Company press releases emphasize cardiometabolic and inflammatory diseases, with a particular focus on obesity, chronic weight management, and inflammation in atherosclerotic cardiovascular disease.
Much of Veru’s recent news has centered on enobosarm, a selective androgen receptor modulator (SARM) being developed to make weight reduction by GLP-1 receptor agonist (GLP-1 RA) drugs more tissue selective for fat loss while preserving lean mass and physical function. Updates include topline efficacy and safety data from the Phase 2b QUALITY study and its Maintenance Extension, which evaluated enobosarm in older patients receiving semaglutide for weight reduction. The company has reported that enobosarm plus semaglutide preserved lean mass, increased fat loss, and reduced declines in stair climb power compared to placebo plus semaglutide, as well as reduced weight and fat regain after semaglutide discontinuation.
Investors following VERU news will also see announcements about regulatory interactions and trial design. Veru has disclosed a successful FDA meeting that, according to the company, provided regulatory clarity for enobosarm as a muscle preservation drug in combination with GLP-1 RA therapy for obesity, including guidance that incremental weight loss can serve as an acceptable primary endpoint and confirmation of the 3 mg dose for future development. News releases describe the planned Phase 2b PLATEAU study, designed to evaluate enobosarm 3 mg in patients with obesity initiating GLP-1 RA treatment, with endpoints focused on total body weight, body composition, and physical function.
Additional VERU headlines cover capital markets activity and corporate actions, such as an underwritten public offering to fund enobosarm development, a 1-for-10 reverse stock split, and Nasdaq notifications regarding minimum bid price compliance. Conference presentations at scientific meetings, collaborations on a modified release enobosarm formulation using Laxxon Medical’s SPID-Technology, and periodic financial results also feature prominently in the company’s news stream.
For investors and observers, the Veru news page provides a consolidated view of clinical trial milestones, FDA-related updates, financing transactions, and scientific presentations that shape the outlook for VERU’s cardiometabolic and inflammatory disease programs.
Veru Inc. presented a meta-analysis of enobosarm's effects on body composition in older obese patients at ObesityWeek 2024. The analysis, based on four previous clinical trials, showed that enobosarm 3mg treatment led to better outcomes compared to placebo. By Day 147, enobosarm-treated subjects showed greater total weight loss (-2.93kg vs -2.11kg placebo), better lean mass preservation (-0.79kg vs -1.77kg placebo), and increased fat mass reduction (-2.05kg vs -0.05kg placebo). The drug was well-tolerated with no increase in gastrointestinal side effects.
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, has announced its participation in ObesityWeek, scheduled for November 3-6, 2024, in San Antonio, Texas. The company will present a meta-analysis of subjects from four randomized clinical trials supporting the potential of enobosarm to optimize weight loss. This presentation, titled "Meta-analysis of subjects from 4 randomized clinical trials supports the potential of enobosarm to optimize weight loss," is set for November 5, 2024, from 2:30 PM to 3:30 PM CDT at the Henry B. González Convention Center.
Veru focuses on developing innovative medicines for preserving muscle for high-quality weight loss, oncology, and viral-induced acute respiratory distress syndrome. The presentation at ObesityWeek aligns with the company's research efforts in weight management and muscle preservation.
Veru Inc. (NASDAQ: VERU) announced its participation in the World Obesity and Weight Management Congress, scheduled for October 24-26, 2024, in Baltimore, Maryland. The company will deliver a keynote presentation on October 25, 2024, from 9:40 AM to 10:20 AM EDT at the Best Western Plus Hotel & Conference Center.
The presentation, titled 'Advancing enobosarm, an oral novel Selective Androgen Receptor Modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) drugs for potentially higher quality weight loss', will focus on the scientific support for combining enobosarm with GLP-1 receptor agonists to preserve muscle during weight loss.
Veru Inc. is a late clinical stage biopharmaceutical company developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome.
Veru Inc. (NASDAQ: VERU), a late-stage biopharmaceutical company, will present at the 2024 Cantor Global Healthcare Conference on September 18th at 1:55 PM Eastern Time. Dr. Mitchell Steiner, the company's Chairman, President, and CEO, will provide a corporate update focusing on Veru's Phase 2b clinical development program of enobosarm.
The presentation will highlight enobosarm's potential to enhance fat loss and prevent muscle loss when used in combination with GLP-1 drugs for weight loss. This aligns with Veru's mission to develop innovative medicines for preserving muscle in high-quality weight loss, oncology, and viral-induced acute respiratory distress syndrome.
Investors can access a live webcast of the presentation through Veru's website, with an archived version available afterward.
Veru Inc. (NASDAQ: VERU) has reached full enrollment of over 150 patients for its Phase 2b QUALITY clinical study of enobosarm in combination with semaglutide (Wegovy®) for obesity. The study aims to evaluate enobosarm's efficacy in preserving muscle mass and enhancing fat loss in patients using GLP-1 drugs for weight management. Topline data for the primary endpoint of lean body mass is expected in January 2025.
Financial highlights for Q3 FY2024 include:
- Net revenues increased to $4.0 million from $3.3 million
- Gross profit increased to $1.3 million from $1.2 million
- Research and development expenses decreased to $4.9 million from $8.8 million
- Net loss was $11.0 million, or $0.07 per share, compared to $12.5 million, or $0.14 per share
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, has announced it will host a conference call and audio webcast on August 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 third quarter financial results and provide a business update. The company focuses on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome.
Investors can access the audio webcast on Veru's website under the Investors page. To join the conference call, participants can dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international). An archived version of the webcast will be available for replay on the company's website for approximately three months, and a telephonic replay will be accessible for one week.
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, has announced its participation in the BTIG Virtual Biotechnology Conference on August 5th, 2024. The company will engage in one-on-one meetings with investors during the event.
Veru specializes in developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome. This conference participation provides an opportunity for Veru to connect with potential investors and showcase its latest developments in these critical areas of medical research.
The virtual format of the conference aligns with the ongoing trend of digital interactions in the biotechnology sector, allowing for efficient and widespread engagement with the investment community.
Veru (NASDAQ: VERU), a late clinical stage biopharmaceutical company, announced its participation in the Leerink Therapeutics Forum: I&I and Metabolism on July 9th, 2024, in Boston, Massachusetts. Veru is focused on developing innovative medicines for muscle preservation, weight loss, oncology, and viral-induced acute respiratory distress syndrome. The company aims to leverage this platform to showcase its latest developments and clinical progress. This participation underscores Veru's commitment to advancing therapeutic solutions in its core areas of focus.
Veru announced data from two late-breaking presentations at the American Diabetes Association's 84th Scientific Sessions held June 21-24, 2024, in Orlando, Florida. The presentations highlighted the safety and efficacy of enobosarm, a drug aimed at muscle preservation and high-quality weight loss. A pooled safety analysis (Poster #2067-LB) involving 1,027 subjects indicated that enobosarm was well-tolerated with similar adverse event rates to placebo, though elevated ALT levels were noted in 3.7% of enobosarm subjects versus 1.4% for placebo. A meta-analysis (Poster #2066-LB) involving 367 subjects showed enobosarm reduced fat mass by 6.26% and increased lean mass by 4.04% over placebo, suggesting its potential to improve weight loss quality.
Veru Inc. (NASDAQ: VERU) has adjourned its 2024 Annual Shareholders Meeting, initially scheduled for June 18, 2024, to June 27, 2024, due to a lack of quorum. The meeting was convened without any business conducted as only 49.6% of shareholders' proxies were submitted, short of the required majority. Shareholders who previously voted do not need to take any further action; their votes will be counted in the rescheduled meeting unless revoked. The record date remains April 29, 2024. Shareholders are encouraged to vote to avoid additional costs.